Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
17 Novembre 2022 - 6:26AM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, today announced the
pricing of an underwritten public offering of 30,500,000 shares of
its common stock at a price to the public of $1.15 per share,
before underwriting discounts and commissions. The gross proceeds
to Biodesix from the offering, before deducting underwriting
discounts and commissions and other offering expenses payable by
Biodesix, are expected to be $35.1 million. The offering is
expected to close on November 21, 2022, subject to customary
closing conditions. Additionally, Biodesix has granted the
underwriters a 30-day option to purchase up to an additional
4,575,000 shares of its common stock at the public offering price,
less underwriting discounts and commissions. All of the shares of
common stock in the offering will be sold by Biodesix.
William Blair is acting as sole bookrunning manager for the
offering.
The shares are being offered by Biodesix pursuant to a shelf
registration statement on Form S-3 that was initially filed with
the Securities and Exchange Commission (“SEC”) on November 15, 2021
and declared effective by the SEC on November 29, 2021. The
offering is being made by means of a prospectus supplement and
accompanying prospectus that form part of the registration
statement. A preliminary prospectus supplement and accompanying
prospectus relating to, and describing the terms of, the offering
has been filed with the SEC and is available on the SEC’s website
at www.sec.gov. A final prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC.
Copies of the prospectus supplement and the accompanying prospectus
relating to this offering can be obtained by contacting: William
Blair & Company, L.L.C., Attention: Prospectus Department, 150
North Riverside Plaza, Chicago, IL 60606, by telephone at (800)
621-0687, or by email at prospectus@williamblair.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy, as well as statements relating to the
Company’s plans to consummate its proposed public offering, the
size of the offering and its intended use of the net proceeds
therefrom. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. The Company's ability to continue as a going concern
could cause actual results to differ materially from those
contemplated in this press release and additionally, other factors
that could cause actual results to differ materially from those
contemplated in this press release can be found in the Risk Factors
section of Biodesix’s most recent annual report on Form 10-K, filed
March 14, 2022 or subsequent quarterly reports on Form 10-Q during
2022, if applicable. Biodesix undertakes no obligation to revise or
publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221116006115/en/
Media: Robin Harper Cowie robin.cowie@biodesix.com (720)
509-8841
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Lug 2023 a Lug 2024